- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06087458
Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (JOURNEY)
Studio di fase 1/2a di incremento della dose di VOY-101 in pazienti con degenerazione maculare avanzata non neovascolare correlata all'età
The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The study has a prospective, open-label, multi-center, two-part design to evaluate a single, unilateral intravitreal (IVT) injection of VOY-101 in subjects with geographic atrophy (GA), the advanced form of non-neovascular age-related macular degeneration (AMD). Phase 1 followed a standard dose escalation model to establish safety and tolerability of VOY-101 and determine the recommended phase 2 dose. This dose is being used in the randomized Phase 2 part of the study to evaluate the safety and efficacy of VOY-101 in the study eye compared to untreated fellow eye.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2000
- Sydney Retina Clinic and Day Surgery
-
-
Victoria
-
East Melbourne, Victoria, Australia, 3002
- Cerulea Clinical Trials
-
-
-
-
-
Haifa, Israele
- Rambam Medical Center
-
Tel Aviv, Israele, 64239
- Tel-Aviv Sourasky Medical Center, Ophthalmology Division
-
-
-
-
Arizona
-
Scottsdale, Arizona, Stati Uniti, 85255
- Retina Macula Institute of AZ
-
-
California
-
Poway, California, Stati Uniti, 92064
- Retina Consultants San Diego
-
Sacramento, California, Stati Uniti, 95825
- Retinal Consultants Medical Group
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Ophthalmic Consultants of Boston
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63128
- The Retina Institute
-
-
New Jersey
-
Cherry Hill, New Jersey, Stati Uniti, 08034
- Mid Atlantic Retina
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97221
- Retina Northwest
-
-
South Dakota
-
Rapid City, South Dakota, Stati Uniti, 57701
- Black Hills Regional Eye Institute
-
-
Texas
-
Austin, Texas, Stati Uniti, 78705
- Austin Research Center for Retina
-
Fort Worth, Texas, Stati Uniti, 76132
- Star Retina
-
Southlake, Texas, Stati Uniti, 76092
- Retina Center of Texas
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84132
- University of Utah John A. Moran Eye Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Are ≥60 years of age at the time of consent.
- Are willing and able to understand and provide written informed consent.
- Are willing and able to return for scheduled treatment and follow-up examinations.
- Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
- Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes.
- Absence of signs of non-exudative MNV.
- Additional Ocular Inclusion Criteria for both eyes.
- Meet certain genotype criteria for risk of AMD.
Exclusion Criteria:
- Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.
- Additional Systemic, Ocular, and Genetic Exclusion Criteria.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Low
Single, unilateral, intravitreal injection of low dose of VOY-101 |
VOY-101 |
|
Sperimentale: Medium
Single, unilateral, intravitreal injection of medium dose of VOY-101 |
VOY-101 |
|
Sperimentale: High
Single, unilateral, intravitreal injection of high dose of VOY-101 |
VOY-101 |
|
Sperimentale: Higher
Single, unilateral, intravitreal injection of higher dose of VOY-101 |
VOY-101 |
|
Sperimentale: Intermediate
Single, unilateral, intravitreal injection of intermediate dose of VOY-101 |
VOY-101 |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Phase 1: To evaluate the safety and tolerability of a single intravitreal injection of escalating doses of VOY-101
Lasso di tempo: 24 Months
|
Frequency and type of ocular and systemic adverse events and non-serious treatment-emergent adverse events |
24 Months
|
|
Phase 1: Change from Baseline in markers of inflammation
Lasso di tempo: Baseline to Month 24
|
Change from Baseline in markers of inflammation including anterior chamber cells, vitreous cells, and retinal vasculitis and retinitis. |
Baseline to Month 24
|
|
Phase 1: Establish the recommended Phase 2 dose in subjects with Geographic Atrophy.
Lasso di tempo: Month 12
|
Determine whether the maximum tolerated dose (MTD) has been reached (as determined by the occurrence of dose-limiting toxicities [DLTs]) and select the RP2D. |
Month 12
|
|
Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on change in Geographic Atrophy lesion size.
Lasso di tempo: 15 Months
|
Change from Baseline in Geographic Atrophy lesion size |
15 Months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Phase 1: To evaluate the effect of VOY-101 on geographic atrophy lesion size and photoreceptors
Lasso di tempo: Baseline through 24 Months
|
Growth rate of total geographic atrophy lesion size and photoreceptor change |
Baseline through 24 Months
|
|
Phase 1/2: To establish the pharmacokinetic (PK) profile of VOY-101.
Lasso di tempo: Baseline through 24 Months
|
Change from Baseline for complement levels in aqueous humor |
Baseline through 24 Months
|
|
Phase 1/2: To evaluate the effect of VOY-101 on best corrected distance visual acuity
Lasso di tempo: 24 Months
|
Change from Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) BCDVA and Percentage of subjects with <15 letters lost in BCDVA from Treatment |
24 Months
|
|
Phase 1/2: Development of macular neovascularization
Lasso di tempo: Month 24
|
Incidence, frequency, severity, and timing of development of macular neovascularization |
Month 24
|
|
Phase 2: To further characterize the ocular and systemic safety and tolerability of VOY-101
Lasso di tempo: 24 Months
|
Frequency of Investigational Product related ocular and systemic adverse events, adverse events of special interest and non-serious treatment-emergent adverse events. |
24 Months
|
|
Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on geographic atrophy lesion size and photoreceptors
Lasso di tempo: Baseline through Month 24
|
Change in geographic atrophy lesion size and rate of photoreceptor loss |
Baseline through Month 24
|
|
Phase 2: To evaluate the effect of VOY-101 on low luminance visual acuity
Lasso di tempo: Baseline through Month 24
|
Change from Baseline in the change in visual function using Early Treatment Diabetic Retinopathy Study (ETDRS) Low Luminance Visual (LLVA) vision test |
Baseline through Month 24
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Anne Fung, MD, Perceive Biotherapeutics, Inc.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- PBI-AMD-002
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .